Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402425 | 1.00 | FLT3 (0.49) | FLT3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30008168 | 0.91 | FLT3 (0.52) | FLT3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2301216 | 0.91 | FLT3 (0.52) | FLT3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29402151 | 0.86 | FLT3 (0.54) | FLT3MEN1KMT2A | |
| SCHEMBL2302040 | 0.86 | FLT3 (0.54) | FLT3MEN1KMT2A | |
| SCHEMBL2301607 | 0.82 | FLT3 (0.49) | FLT3 | |
| SCHEMBL29400009 | 0.82 | FLT3 (0.49) | FLT3 | |
| SCHEMBL2301360 | 0.80 | ALDH1A1 (0.56) | FLT3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29402574 | 0.80 | ALDH1A1 (0.56) | FLT3MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2301433 | 0.79 | MEN1 (0.42) | FLT3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | claimed |
| WO-2011103557-A1 | SMALL MOLECULE INHIBITORS OF PFKFB3 AND GLYCOLYTIC FLUX AND THEIR METHODS OF USE AS ANTI-CANCER THERAPEUTICS | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-08-25 | — | — | WO | claimed |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240269124-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240262916-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-116615241-A | Methods and compositions for diabetes treatment and beta cell regeneration | 加利福尼亚大学董事会 | 2023-08-18 | — | — | CN | disclosed |
| EP-4200016-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040161-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2017208174-A2 | METHODS OF TREATING DISEASE WITH PFKFB3 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | WO | disclosed |
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | IAPP, APP, SLC2A3 | FLT3 1893/4885MEN1 4289/4885NPC1 2466/4885 |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | PFKFB3, PFKFB1, PFKFB2 | FLT3 672/4885MEN1 2284/4885NPC1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.